Validation study of colorectal cancer treatment effect prediction by metabolomic markers

ABSTRACT: Primary outcome(s): Best clinical response (RECIST 1.1) Serum concentration of metabolomic markers

DISEASE(S): Colorectal Cancer

PROVIDER: 2652805 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR